Unawareness of hypoglycaemia and human insulin
Human insulin almost exonerated A fall in plasma glucose concentration below normal usually elicits a characteristic hierarchy of responses.' At a concentration of about 3-8 mmol/l the secretion of counterregulatory hormones increases and activation of the autonomic nervous system occurs. Should the decrease in concentration persist or progress, additional release of neurohormones produces autonomic warning symptoms (sweating, anxiety, palpitations, hunger, and tremor), which may prompt the affected person to take protective action (that is, to ingest carbohydrate). These warning symptoms generally occur at a plasma glucose concentration of 3-4 mmol/l, which is about 0-5 mmol/l above that at which neuroglycopenic symptoms and cognitive dysfunction begin.
The failure of autonomic warning signals to occur before neuroglycopenia develops is commonly referred to as hypoglycaemia unawareness.2 First described shortly after the introduction of animal insulin, it has also been noted in patients with insulinoma, spinal cord section, ganglionic blockade, and autonomic neuropathy.2 In insulin dependent diabetic patients it is associated with a long duration of diabetes, frequent episodes ofsevere hypoglycaemia, and strict glycaemic control, though not necessarily with autonomic neuropathy.2~4 Patients with insulin dependent diabetes require more severe hypoglycaemia to initiate secretion of counterregulatory hormone and reduce secretion ofadrenaline and noradrenaline.5 Episodes of hypoglycaemia may induce these changes6; aside from this, other causes remain speculative.
One speculation, which has received considerable attention in the lay and scientific press, is that human insulin may diminish patients' awareness of hypoglycaemia, thereby increasing the risk of severe hypoglycaemia. This issue was reviewed in 19877 and again in 198989; both times no conclusive evidence was found. In fact, this was the conclusion of an expert panel of the United States Food and Drug Administration after a public hearing in 1989. Two articles in this issue ofthe journal again review this question and propose the need for a large multicentre randomised trial (p 355,'1 p 351"). In 1989, on the basis of available evidence, most practitioners, professional diabetes organisations, and government agencies did not consider human insulin to be an important threat to health. Has there been additional incriminating evidence since 1989 to warrant undertaking a large multicentre trial? Such a study would be justified if the hypothesis of harm was plausible or if the outcome could improve the safety and efficacy of treatment. Regarding plausibility, nothing has changed. As Williams and Patrick'" point out, there is still no established physiological basis for an intrinsic effect of human insulin to alter autonomic activation in response to hypoglycaemia and to reduce awareness of hypoglycaemia. This would presumably have to occur as a result of insulin acting on the brain or the endothelial cells of the blood-brain barrier. Because human and porcine insulin bind to insulin receptors identically differential access to receptors must be postulated. But there is no evidence for such an effect. The subtle difference in subcutaneous absorption between human and porcine insulins is trivial when compared with the intrasubject variations in subcutaneous absorption of both insulins. Thus how human insulin could intrinsically reduce autonomic activation in response to hypoglycaemia remains a mystery.
Furthermore, the studies cited by Egger et al"' and others not cited'2'4 indicate that no new evidence exists that human insulin reduces plasma catecholamine responses to hypoglycaemia. In fact, the opposite is true. All nine studies since 1989 that compared porcine and human insulin found no significant difference in plasma catecholamine responses or autonomic symptoms. Egger et al suggest that the small number of subjects studied may have limited the power to detect a difference. " Maran et al, however, studied 17 patients with insulin dependent diabetes in a double blind crossover trial, using the sensitive stepwise hypoglycaemic clamp technique, and found no difference."' Such a study should have had the power to detect a clinically important difference if one existed. In summary, there remains no known physiological basis by which human insulin can intrinsically affect autonomic activation in response to hypoglycaemia, and direct comparisons of human and porcine insulins under carefully controlled conditions persistently fail to show that human insulin reduces plasma catecholamine responses to hypoglycaemia. One can therefore seriously question the plausibility of the hypothesis for the proposed multicentre study.
This conclusion is supported by postmarketing surveys and many other studies, which have failed to show an increased frequency of severe hypoglycaemia in patients treated with human insulin (as pointed out by both Williams and Patrick'°3 and Egger et all'). Although most data come from less than optimally designed studies or ones not specifically undertaken to address this issue, this great mass of negative results cannot simply be dismissed. Moreover, two recent double blind crossover trials in 67 patients with insulin dependent diabetes found no difference in the frequency of hypoglycaemia during treatment with porcine and human insulins. The study by Colagiuri et al had the statistical power to detect a 20% increase in frequency. '5 Thus, viewing the scientific literature as a whole, there seems no rationale for supporting the hypothesis that human insulin has the intrinsic ability to reduce the awareness of hypoglycaemia, and there is no convincing evidence that its use intrinsically increases the risk of severe hypoglycaemia.
Despite this, considerable concern still exists among patients and doctors. Excluding a specific effect in a small subpopulation of patients or a small increase in risk (for example, less than 20%) is not possible on the basis of current published studies. An additional study with a design identical with that used by Colagiuri et al'5 would alleviate this concern if both studies' results were the same, as their combined power could exclude a clinically important effect. Such a study, rather than an expensive large scale multicentre study, would therefore seem indicated.
At present, the following recommendations seem reasonable: concerned patients and doctors should be informed of the current status of evidence against human insulin, patients satisfactorily treated with porcine insulin should not routinely be transferred to human insulin, patients who want to transfer from human insulin should be able to, and preparations of animal insulins should remain available until the appropriate study has put this issue to rest.'6 JOHN E GERICH Whittier Institute for Diabetes and Endocrinology, La Jolla, California 92037, USA "AIDS" without HIV: fire without smoke Claims ofa new strain ofHIV are premature Delegates returning from the international conference on AIDS in Amsterdam were surprised to find that press coverage in both the United States and the United Kingdom had been dominated by an issue that had been ignored during the formal scientific sessions and had received only cursory mention during the conference summaries. The stories at home were dominated by a few patients who seemed to have AIDS but no HIV.
Press attention had been directed to an additional scientific session and subsequent press conference at which Dr Jeffrey Laurence from Cornell University announced first details of an investigation of five patients from a large HIV practice who had signs or symptoms consistent with AIDS or AIDS related complex but from whom HIV-1 and HIV-2 had never been detected by antibody testing, virus isolation, or molecular detection techniques, including the polymerase chain reaction. Four patients had risk factors for the acquisition of HIV, and infection with human T cell leukaemia/lymphoma virus types I and II had been excluded by immunoblotting.
At the same session Dr James Curran, head of the AIDS section at the Centers for Disease Control, Atlanta, reported that the centres had received information on a further six cases, which were now under investigation. In the following discussion scientists representing several research groups, including Professor Luc Montagnier, who discovered HIV, reported brief details on a few additional cases at various stages of investigation.
At this point the world's press proposed a series of emotive questions quite out of proportion with the limited clinical data presented. These included the safety of national blood supplies and the extent of risk to those in high risk categories for HIV infection but who remained negative for HIV antibody. Although not raised two weeks ago, further questions of the more general relevance of HIV to the pathogenesis of AIDS will no doubt soon follow. One week later the Lancet carried a brief report of the cases in New York City, which contained little further documentation.' Indeed, one of the patients had no clinical indication of immunodeficiency other than infection with Mycobacterium tuberculosis and two slightly low CD4 counts, which could have been secondary to his acute illness.2 Preliminary information about reverse transcriptase activity in cultures of lymphocytes from two patients will require further confirmation, and no viral isolates were reported. In many ways the limited scientific debate in Amsterdam was reminiscent of that in the early days of the AIDS epidemic. In 1981-3, before HIV had been isolated and identified, the cause of the new syndrome aroused widespread speculation and investigation, which ended with the description of the new virus and the development of a highly sensitive and specific diagnostic antibody test. The driving forces then for a scientific search for a transmissible cause were the epidemic rise in numbers of newly identified and reported cases and the careful early epidemiological studies that suggested a pattern of spread similar to that of known viral infections such as hepatitis B. These epidemiological studies BMJ VOLUME 305 8 AUGUST 1992
